Pershing Square Activist Presentation Deck
Generics Manufacturers May Challenge
Existing Patents
► Risk of successful patent challenges greatest for "Life
Extension" patents
► Allergan recently received negative news on Latisse, which
employs the same active ingredient used in another AGN
product, Lumigan
Allergan loses Latisse patent fight, jeopardizing up to $200M in sales
"The U.S. Court of Appeals for the Federal Circuit in Washington has
deemed a pair of Latisse patents invalid, paving the way for Novartis'
Sandoz unit and the generics maker Apotex to sell their copies. The patents
on Latisse--a variation of Allergan's Lumigan, used to treat glaucoma--cover
ways to apply the drug to promote eyelash growth. But that growth is a
'known potential side effect of glaucoma treatments, the court ruled,
rendering Allergan's patent claims obvious."
- Fierce Pharma; June 11, 2014
58View entire presentation